This clinical trial’s purpose is to test a new study drug, called AZD0780. The study drug is a small molecule PCSK9 inhibitor that aims to lower the levels of “bad cholesterol” in the blood.

Volunteers who join the trial will take AZD0780(study drug) orally, every day for 12 weeks, which is about three months. Your participation in the study will help to determine the
effectiveness, safety, and tolerability of AZD0780(study drug) and how it affects LDL-C (bad cholesterol) levels and levels of other types of fat in your blood.

You may qualify if you:

  • Are male or female of non-childbearing potential within an age range from 18 to 75 years.
  • Fasting LDL-C levels (bad cholesterol): Between 70mg/dL (1.8 mmol/L) and < 190 mg/dL (4.9 mmol/L).
  • Fasting triglycerides: < 400 mg/dL (< 4.52 mmol/L).
  • Are receiving moderate or high-intensity statin therapy as per ACC/AHA (at least 2 months prior to screening).
  • Body mass index (BMI): ≥ 19.0 kg/m2.
  • Are capable of providing signed informed consent and comply with study requirements.

Contact us for more information: 786-772-0510

Active-controlled study to assess the efficacy, safety, and tolerability of investigational drug Baxdrostat in combination with Dapagliflozin compared with Dapagliflozin alone on chronic kidney disease (CKD) progression in participants with CKD and high blood pressure.

    • VA: Greetings, I am Indago's Virtual Assistant. Kindly note that the information I provide may not be guaranteed for accuracy and my voice is AI generated. How may I help you? También hablo español y otros idiomas

    Virtual Assistant is thinking ...
  • Virtual Assistant
    Skip to content